

00270

PATENT TRADEMARK OFFICE



Please type a plus sign (+) inside this box ->

PTO/SB/21 (08-00)

TRANSMITTAL FORM			Application Number	09/700,329				
		Filing Date	February 28, 2001					
		First Named Inventor	P. Gevas, et al.					
(to be used for all correspondence after initial filing)		Group Art Unit	1631					
			Examiner Name	M. Borin				
Total Number of Pages in this Submission		24	Attorney Docket Number	M. Borin				
ENCLOSURES (check all that apply)								
Fee Transmittal Form			nent Papers (for an Application)	☐ After Allowance Communication to Group				
Fee Attached	•••	Drawing		Appeal Communication to Board of Appeals and				
⊠ <sub>Amendment</sub> /Reply		☐ Licensing-related Papers		Interferences				
☐ After Final		☐ Petition		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
☐ Affidavits/declaration(s)		Petition to Convert to a Provisional		☐ Proprietary Information				
☐ Extension of Time R	Request	Appli Power of	of Attorney, Revocation	☐ Status Letter				
Express Abandonme	ent Request	Change of Correspondence Address  Terminal Disclaimer		☑Other Enclosure(s) (please identify below):  . Response to Notice to Comply with Requirements For Patent Applications				
Information Disclose								
Certified Copy of Pr Document(s)	riority	Request	for Refund	Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure Statement To Support Filing and Submission In Accordance with				
Response to Missing	2							
Parts/Incomplete Application				37CFR§1.821 Through §1.825				
Response to Missing CFR 1.52 or 1.53	g Parts under 37							
		Remarks:						
		RECEIVED  MAY 0 3 2002  RECEIVED  APR 2 6 2002  TECH CENTER 1600						
		RECEIVED APR 26						
			MAY 0 3 2002 /ECH CENTED 2002					
			TECH CENTER 1600/2900					
RECEIVED  MAY 0 3 2002  TECH CENTER 1600/2900  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm <i>or</i> Individual Name	Mary E. Bak, HOWSON AN		ON	RECEIVED				
Signature	May			SEP 1 2 2003				
Date	April 25, 20			TECH CENTER 1600/2900				
	-		ERTIFICATE OF MAILING					
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:								
Typed or printed name								
Signature				Date				



MAY 0 3 2002 A JECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of	f	) Group Art Unit: 1631		
P. Gevas et al.		) Examiner: M. Borin		
Appln. No. 09/700,329		)	23	
Filed: February 28, 20	001	)	部82	OF REC
For: PREVENTION HYPERGAST	I AND TREATMENT OF RINEMIA	) April 25, 2002	5 PH 2:	
BOX SEQUENCE Assistant Commissione Washington, DC 2023	)	ယ ယ ယ	/2000	

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

SEQUENCE ON AMINO ACID SEQUENCE DISCLOSURE

SEA CONTAINING NUCLEOTIDE
SEQUENCE ON AMINO ACID SEQUENCE DISCLOSURE

SEA CONTAINING NUCLEOTIDE
SECUENCE ON AMINO ACID SEQUENCE DISCLOSURE

SEA CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEA CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEA CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEA CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEQUENCE

Sir:

In a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", dated March 28, 2002, Applicant was informed that the above-identified application failed to comply with the requirements of 37 CFR § 1.821-1.825. Specifically, Applicant was informed that:

- (i) The application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR § 1.821(c);
- (ii) A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR § 1.821(e). A paper copy is in the file but is not in accordance with new Sequence Listing Rules; and
- (iii) Applicant is also requested to provide SEQ ID numbers for peptide sequences in the specification and claims.

In response to that Notice, Applicant asserts that pursuant to 37 CFR § 1.821-1.825, a paper copy of the "Sequence Listing", a computer readable form (CRF) of the "Sequence Listing", a Statement to Support Filing and Submission, and an Amendment inserting the Sequence ID numbers were originally filed with the application. As support, Applicant encloses herewith as Exhibits A-C, a copy of the stamped postcard indicating receipt by the US Patent and Trademark Office of the above-noted items, the originally filed paper copy of the "Sequence Listing", and the Preliminary Amendment inserting the sequence ID numbers into the originally filed application. Further, Applicant asserts that the paper copy filed with the application and enclosed herewith as Exhibit B did conform with the new Sequence Listing rules.

However, in an effort to expedite examination of this application and in response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" which was dated March 28, 2002, to which a response is due by April 28, 2002, enclosed herewith are:

( ) Amendment under 37 CFR § 1.825; Statement to Support Filing and Submission in accordance with 37 CFR **(X)** §§ 1.821 through 1.825; ( ) Original pages of the Sequence Listing; **(X)** Substitute copy of the pages of the Sequence Listing; ( ) Original computer readable form of the Sequence Listing; **(X)** Substitute copy of the computer readable form of the Sequence Listing; **(X)** Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; ( )Petition for a month Extension of Time to Reply;

( )

OTHER:

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

**HOWSON AND HOWSON** Attorneys for the Applicant

By Mary E. Bak Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477 Telephone: (215) 540-9206

Telefacsimile: (215) 540-5818

## ACG2AUSA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of		) Group Art Unit: 1631		
P. Gevas et al.		) Examiner: M. Borin		
Appln. No. 09/700,329				
Filed:	February 28, 2001			
For:	PREVENTION AND TREATMENT OF HYPERGASTRINEMIA	) April 25, 2002 <b>RECEIVED</b> ) MAY 0 3 2002		
BOX S	SEQUENCE	TEOU CENTED 4000/0000		
Assista	nt Commissioner for Patents	1EUN UENTER 1000/2900		
Washin	ngton, DC 20231	PECA		
	IN ACCORDANCE WITH 37 CFR §1.	821 THROUGH §1.87 CH CENTED 2 2003		
	SEQUENCE istant Commissioner for Patents  Shington, DC 20231  STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §1.821 THROUGH §1.87 CFC  (X) I hereby state, in accordance with the requirements of 37 CFR  §1.821(f) and to the best of my knowledge and belief that the Sequence			

- (X) §1.821(f) and to the best of my knowledge and belief that the Sequence Listing information recorded in computer readable form is identical to the written (on paper or compact disc) Sequence Listing, submitted pursuant to 37 CFR §1.821(c) and (e), respectively.
- **(X)** I hereby state that to the best of my knowledge and belief the submission filed in accordance with the requirements of 37 CFR §1.821(g), does not include new matter.
- ( )I hereby state that to the best of my knowledge and belief the submission filed in accordance with the requirements of 37 CFR §1.821(h) does not include new matter or go beyond the disclosure of the international application as filed.
- ( ) I hereby state that to the best of my knowledge and belief the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing do not include new matter. These amendments were made to conform with the current Sequence Listing Rules and to correct a typographical error in the Sequence Listing.

- () I hereby state that to the best of my knowledge and belief the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- ( ) I hereby state that to the best of my knowledge and belief the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

**HOWSON AND HOWSON** Attorneys for the Applicant

Mary E/Bak
Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477

Telephone: (215) 540-9206

Telefacsimile: (215) 540-5818